Skip to main content
Clinical Trials/EUCTR2006-006390-24-DE
EUCTR2006-006390-24-DE
Active, not recruiting
Not Applicable

Prospektive, randomized, controlled, multicentre, partly double blind study to compare Disci/Rhus toxicodendron comp., placebo and waiting list in patients with chronic low back pain.

WALA Heilmittel GmbH0 sitesJanuary 24, 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
chronic low back pain (chronic local or pseudoradiculaere low back pain due to e.g. degenerative basic illness).
Sponsor
WALA Heilmittel GmbH
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 24, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • History of chronic low back pain (chronic local or pseudoradiculaere clow back pain due to e.g. degenerative basic illness).
  • \=\> Back pain for at least 12 month prior inclusion (\= chronic low back pain).
  • Average value of pain intensity related to the last 7 days (40mm on a visual analog scale of 0 to 100mm).
  • Therapy of chronic low back pain only medicamentous in the last 4 weeks before enrollment (peripherally active analgesics, non\-steroidal antiphlogistics, muscle relaxants).
  • \=\> effective contraception for women of childbearing potential. Methods of birth control are considered to effective, when failure rate is less than 1% per year, e.g. combined oral contraceptives, implants, IUDs, diphragm, occlusive pessary or sexual abstinence.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Treatment with Disci medicinal products.
  • Concomitant therapy with other drugs than peripheral active analgesic, non\-steroidal antiphlogistics.
  • Necessity of taking analgesics due to other disease.
  • Protrusion or prolapse of one/more intervertebral disks with neurological symtomatic.
  • History of surgery of the spine or planned surgeries.
  • History of infectious spondylopathy.
  • History of back pain due to a malignant and inflammatory illness.
  • History of ankylosing spondylitis, Reiter´s syndrome, Morbus Behcet.
  • History of congenital malformation of spine expecting mild lordosis or scoliosis.
  • History of osteoporosis, spinal stenosis, spondylolysis, spondylolisthosis.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Prospective, randomized, controlled, multicenter, operative study to evaluate the role of intraoperative sonography compared to the preoperative wire localization in the treatment of non-palpable breast cancerC50Malignant neoplasm of breast
DRKS00010174niversitätsfrauenklinik230
Completed
Not Applicable
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of pelvic floor biofeedback training with ACTICORE1® for stress incontinence?N39.3Stress incontinence
DRKS00027319ACTICORE GmbH124
Not yet recruiting
Not Applicable
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of app-based biofeedback training with ACTICORE1® for female stress incontinence?N39.3Stress incontinence
DRKS00033971ACTICORE GmbH262
Active, not recruiting
Phase 1
Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for the treament of presby vertigo.Presby VertigoMedDRA version: 20.0 Level: PT Classification code 10047340 Term: Vertigo System Organ Class: 10013993 - Ear and labyrinth disordersTherapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
EUCTR2014-000303-28-DEDr. Willmar Schwabe GmbH & Co. KG120
Withdrawn
Phase 4
Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries.narrowing of the bloodvesselstenosis10003216
NL-OMON35958Eurocor GmbH15